标题
Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma
作者
关键词
-
出版物
Current Oncology Reports
Volume 24, Issue 6, Pages 695-702
出版商
Springer Science and Business Media LLC
发表日期
2022-03-05
DOI
10.1007/s11912-022-01196-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
- (2021) S. Aeppli et al. ESMO Open
- Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
- (2021) Michael R. Harrison et al. CANCER
- Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma
- (2021) Brian I. Rini et al. Clinical Genitourinary Cancer
- Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma
- (2021) Fahad Quhal et al. CURRENT OPINION IN UROLOGY
- A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma
- (2021) Irbaz Bin Riaz et al. EUROPEAN UROLOGY
- Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis
- (2021) Keiichiro Mori et al. CANCER TREATMENT REVIEWS
- Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.
- (2021) Viktor Grünwald et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.
- (2021) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.
- (2021) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer - Combination Therapy in the First Line Setting
- (2020) David H Aggen et al. CLINICAL CANCER RESEARCH
- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- (2020) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment patterns, outcomes and clinical characteristics in advanced renal cell carcinoma: a real-world US study
- (2020) Jennifer P Hall et al. Future Oncology
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
- (2020) Robert J. Motzer et al. NATURE MEDICINE
- Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
- (2020) Matthew D. Tucker et al. Cancers
- Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
- (2020) Robert J. Motzer et al. CANCER CELL
- Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer
- (2020) T. Powles ANNALS OF ONCOLOGY
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma
- (2019) Bernard Escudier NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors
- (2019) Arpita Desai et al. Future Oncology
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
- (2018) Axel Bex et al. JAMA Oncology
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started